Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | BTN3A1 | O00481 | 6/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | LAP3 | P28838 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7027694 | 0.93 | SMN1; SMN2 (0.41) | PRTN3HPGDELANEBTN3A1SMN1; SMN2 | |
| SCHEMBL7027248 | 0.91 | ZDHHC2 (0.42) | PRTN3ELANEBTN3A1SMN1; SMN2 | |
| SCHEMBL15721086 | 0.85 | KMT2A (0.44) | PRTN3LMNAMAPTHPGDELANE | |
| SCHEMBL7027815 | 0.82 | PRTN3 (0.39) | PRTN3LMNAELANEBTN3A1ANPEP | |
| SCHEMBL5857844 | 0.82 | ELANE (0.40) | PRTN3ELANEBTN3A1ANPEPLAP3 | |
| SCHEMBL873273 | 0.82 | BTN3A1 (0.41) | PRTN3LMNAELANEBTN3A1ANPEP | |
| SCHEMBL3971351 | 0.82 | BTN3A1 (0.41) | PRTN3LMNAELANEBTN3A1ANPEP | |
| SCHEMBL7023266 | 0.81 | ELANE (0.40) | PRTN3ELANEBTN3A1ANPEPLAP3 | |
| SCHEMBL3970115 | 0.81 | TSHR (0.39) | PRTN3ELANEBTN3A1 | |
| SCHEMBL3970116 | 0.81 | TSHR (0.39) | PRTN3ELANEBTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1117669-B1 | ANTIVIRAL PURINE DERIVATIVES | UNIV CARDIFF (GB) | 2003-01-29 | — | — | EP | disclosed |
| US-20010031745-A1 | Antiviral purine derivatives | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2001-10-18 | — | — | US | disclosed |
| EP-1117669-A1 | ANTIVIRAL PURINE DERIVATIVES | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LTD. (GB) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018775-A1 | ANTIVIRAL PURINE DERIVATIVES | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031745-A1 | Antiviral purine derivatives | PNP, TYMP, MTAP | PGR 2265/4885SCN1A 4433/4885SCN2A 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.